JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

147.65

+1.19%↑

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Suletud

SektorTervishoid

424.5 1.94

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

413

Max

424.77

Põhinäitajad
By Trading Economics
Sissetulek	31M -42M
Müük	76M 213M
Aktsiakasum	-1.9
Kasumimarginaal	-19.869
Töötajad	528
EBITDA	31M -39M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+21.75% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. nov 2025

Turustatistika
By TradingEconomics
Turukapital	2.9B 9.8B
Eelmine avamishind	422.56
Eelmine sulgemishind	424.5

Uudiste sentiment

By Acuity

50%

163 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. okt 2025, 20:49 UTC

Tulu

Correction to Thermo Fisher Article on Oct. 22

23. okt 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23. okt 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23. okt 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23. okt 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23. okt 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -2-

23. okt 2025, 22:49 UTC

Omandamised, ülevõtmised, äriostud

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23. okt 2025, 22:17 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23. okt 2025, 21:41 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23. okt 2025, 21:05 UTC

Tulu

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23. okt 2025, 20:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

23. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. okt 2025, 20:35 UTC

Tulu

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23. okt 2025, 20:28 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23. okt 2025, 20:15 UTC

Market Talk

Tulu

Global Commodities Roundup: Market Talk

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Adj EPS $1.71

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q Sales $5.52B

23. okt 2025, 20:10 UTC

Tulu

Newmont Mining 3Q EPS $1.67

23. okt 2025, 20:09 UTC

Tulu

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23. okt 2025, 20:07 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

23. okt 2025, 20:07 UTC

Market Talk

Tulu

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23. okt 2025, 20:07 UTC

Tulu

Blackstone Looks to IPOs for Investment Exits -- Update

23. okt 2025, 20:05 UTC

Tulu

Intel 3Q Gross Margin 38.2% >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23. okt 2025, 20:04 UTC

Tulu

Intel: 4Q Guidance Excludes Altera >INTC

23. okt 2025, 20:04 UTC

Tulu

Intel Sees 4Q Adj EPS 8c >INTC

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

21.75% tõus

12 kuu keskmine prognoos

Keskmine 506.43 USD 21.75%

Kõrge 590 USD

Madal 266 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

Osta

Hoia

Müü

Põhineb 16 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

163 / 371 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.